Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe

Home hero background
Female patient with their mother




VPRIV is a lysosomal glucocerebroside-specific enzyme indicated for first-line enzyme replacement therapy (ERT) for type 1 Gaucher disease.1,2

VPRIVʼs safety and efficacy profile was evaluated in the largest clinical trial program of an ERT for type 1 Gaucher disease in 99 patients across three clinical trials, which included pediatric (aged ≥4 years), adult, and geriatric (aged ≥65 years) patients.1,3,4

*Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV5,6
Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV7

Male patient


Hypersensitivity reactions, including anaphylaxis, have occurred. The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.

Hypersensitivity reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of VPRIV.